Form 8-K Apellis Pharmaceuticals, For: Sep 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Wedbush Downgrades Apellis Pharmaceuticals (APLS) to Neutral
September 10, 2021 7:29 AM EDTWedbush analyst Laura Chico downgraded Apellis Pharmaceuticals (NASDAQ: APLS) from Outperform to Neutral with a price target of $39.00 (from $71.00).
The analyst commented, "Our prior upgrade was predicated on the pivotal DERVY/OAKS studies holding a high probability of success (>80%) for at least the monthly... More
Apellis Pharmaceuticals (APLS) PT Lowered to $65 at Oppenheimer
September 10, 2021 6:58 AM EDTOppenheimer analyst Justin Kim lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $65.00 (from $80.00) while maintaining an Outperform rating.
The analyst commented, "On 9/9, Apellis reported mixed top-line results from its Phase 3 DERBY and OAKS studies (n=1,258) of pegcetacoplan in geographic... More
Apellis Pharmaceuticals (APLS) PT Lowered to $70 at Needham & Company
September 10, 2021 6:54 AM EDTNeedham & Company analyst Joseph Stringer lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $70.00 (from $85.00) while maintaining a Buy rating.
The analyst commented, "APLS announced yesterday results from the Ph3 DERBY and OAKS trials evaluating pegcetacoplan in Geographic Atrophy (GA). The... More
Apellis Pharmaceuticals (APLS) PT Lowered to $69 at BMO Capital, Overall Data 'Should Still be Enough'
September 10, 2021 6:40 AM EDTBMO Capital analyst Matthew Luchini lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $69.00 (from $89.00) while maintaining an Outperform rating, saying the "totality of data plus the unmet need in GA provides reasonable basis for approval and recommend taking advantage of current... More
Apellis Pharmaceuticals (APLS) to Resume Trading at 4:35 p.m.
September 9, 2021 4:14 PM EDTApellis Pharmaceuticals (NASDAQ: APLS) to Resume Trading at 4:35 p.m.
